Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To estimate 6-month progression free survival probability of pts w recurrent malignant
gliomas treated w erlotinib + bevacizumab.
Secondary Objectives:
To evaluate safety & tolerability of erlotinib + bevacizumab among pts w recurrent malignant
gliomas To evaluate radiographic response of pts w recurrent malignant gliomas treated w
erlotinib + bevacizumab To evaluate pharmacokinetics of erlotinib when administered to pts w
recurrent malignant gliomas; & to examine relationship of clinical response to Epidermal
Growth Factor (EGFR) expression, amplification, & v-III mutation, phosphatase and tensin
homolog (PTEN) expression, vascular endothelial growth factor (VEGF) expression, vascular
endothelial growth factor receptor 2 (VEGFR-2) & phosphorylated protein kinase B (PKB/Akt) in
archival tumor samples